Improvements in the Synthesis of the Third‐Generation EGFR Inhibitor Osimertinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Improvements in the Synthesis of the Third‐Generation EGFR Inhibitor Osimertinib

Published:2021-10 Issue:11 Volume:104 Page:
ISSN:0018-019X
Container-title:Helvetica Chimica Acta
language:en
Short-container-title:Helv. Chim. Acta

Author:

Voulgari Pinelopi¹^ORCID,Alivertis Dimitrios²^ORCID,Skobridis Konstantinos¹^ORCID

Affiliation:

1. Department of Chemistry University of Ioannina GR-45110 Ioannina Greece

2. Department of Biological Applications and Technology University of Ioannina GR-45110 Ioannina Greece

Funder

European Commission

Publisher

Wiley

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Drug Discovery,Biochemistry,Catalysis

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hlca.202100066

Reference34 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

3. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro

4. Protein kinases — the major drug targets of the twenty-first century?

5. Epidermal growth factor receptor mutations in lung cancer

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP